Host-based ribavirin resistance influences hepatitis C virus replication and treatment response

Journal of Virology

Volumn 85, Issue 14, 2011, Pages 7273-7283

  Ibarra, Kristie D ^a   Jain, Mamta K ^a   Pfeiffer, Julie K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CELL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; HUMAN CELL; LIVER CELL; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 79960424334     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00629-11     Document Type: Article

References (53)

1. Benhamou, Y., et al. 2009. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 50:717-726.
2. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
3. Bougie, I., and M. Bisaillon. 2003. Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J. Biol. Chem. 278:52471-52478.
4. Cai, J., et al. 2008. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 68:2349-2357.
5. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895-6900.
6. Crotty, S., et al. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
7. Dixit, N. M., J. E. Layden-Almer, T. J. Layden, and A. S. Perelson. 2004. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:922-924.
8. Dixit, N. M., and A. S. Perelson. 2006. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol. Life Sci. 63:832-842.
9. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
10. Erickson, A. K., S. Seiwert, and M. Gale, Jr. 2008. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antivir. Ther. 13:851-862.
11. Errasti-Murugarren, E., P. Cano-Soldado, M. Pastor-Anglada, and F. J. Casado. 2008. Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity. Mol. Pharmacol. 73:379-386.
12. Errasti-Murugarren, E., M. Molina-Arcas, F. J. Casado, and M. Pastor-Anglada. 2010. The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs. Mol. Pharmacol. 78:157-165.
13. Errasti-Murugarren, E., M. Pastor-Anglada, and F. J. Casado. 2007. Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J. Physiol. 582:1249-1260.
14. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
15. Feld, J. J., et al. 2010. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 139:154-162.
16. Feld, J. J., et al. 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46:1548-1563.
17. Ferenci, P., et al. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 43:425-433.
18. Fotoohi, A. K., M. Lindqvist, C. Peterson, and F. Albertioni. 2006. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem. Biophys. Res. Commun. 343:208-215.
19. Fukuchi, Y., T. Furihata, M. Hashizume, M. Iikura, and K. Chiba. 2010. Characterization of ribavirin uptake systems in human hepatocytes. J. Hepatol. 52:486-492.
20. Galmarini, C. M., et al. 2002. Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. 26:621-629.
21. Ge, D., et al. 2009. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 461:399-401.
22. Ghany, M. G., D. B. Strader, D. L. Thomas, and L. B. Seeff. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374.
23. Gish, R. G. 2006. Treating HCV with ribavirin analogues and ribavirin-like molecules. J. Antimicrob. Chemother. 57:8-13.
24. Graci, J. D., and C. E. Cameron. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16:37-48.
25. Griffith, D. A., and S. M. Jarvis. 1996. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1286:153-181.
26. Hezode, C., et al. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850.
27. Ibarra, K. D., and J. K. Pfeiffer. 2009. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J. Virol. 83:4538-4547.
28. Jarvis, S. M., J. A. Thorn, and P. Glue. 1998. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br. J. Pharmacol. 123:1587-1592.
29. Jordheim, L. P., and C. Dumontet. 2007. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776: 138-159.
30. Kong, W., K. Engel, and J. Wang. 2004. Mammalian nucleoside transporters. Curr. Drug Metab. 5:63-84.
31. Lindahl, K., L. Stahle, A. Bruchfeld, and R. Schvarcz. 2005. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41:275-279.
32. Loustaud-Ratti, V., A. Rousseau, P. Marquet, F. Denis, and S. Alain. 2009. Ribavirin in chronic hepatitis C: past and future. Expert Rev. Anti Infect. Ther. 7:249-253.
33. Lowe, J. K., L. Brox, and J. F. Henderson. 1977. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res. 37:736-743.
34. Lum, P. Y., L. Y. Ngo, A. H. Bakken, and J. D. Unadkat. 2000. Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. Cancer Chemother. Pharmacol. 45:273-278.
35. Maag, D., C. Castro, Z. Hong, and C. E. Cameron. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:46094-46098.
36. Mangravite, L. M., I. Badagnani, and K. M. Giacomini. 2003. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur. J. Pharmacol. 479:269-281.
37. McHutchison, J. G., et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
38. Morello, J., et al. 2010. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J. Infect. Dis. 202:1185-1191.
39. Patil, S. D., L. Y. Ngo, P. Glue, and J. D. Unadkat. 1998. Intestinal absorption of ribavirin is preferentially mediated by the Na2.nucleoside purine (N1) transporter. Pharm. Res. 15:950-952.
40. Peavy, D. L., C. N. Powers, and V. Knight. 1981. Inhibition of murine plaque-forming cell responses in vivo by ribavirin. J. Immunol. 126:861-864.
41. Pfeiffer, J. K., and K. Kirkegaard. 2005. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 79:2346-2355.
42. Poordad, F., K. R. Reddy, and P. Martin. 2008. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin. Infect. Dis. 46:78-84.
43. Shiffman, M. L. 2009. What future for ribavirin? Liver Int. 29(Suppl. 1):68-73.
44. Sintchak, M. D., and E. Nimmesgern. 2000. The structure of inosine 5 -monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:163-184.
45. Takagaki, K., et al. 2004. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRFCEM-derived cells. J. Biochem. 136:733-740.
46. Tam, R. C., et al. 1999. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30:376-382.
47. Toan, S. V., et al. 2003. Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. Pflugers Arch. 447:195-204.
48. Vo, N. V., K. C. Young, and M. M. Lai. 2003. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42:10462-10471.
49. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
50. Wohnsland, A., W. P. Hofmann, and C. Sarrazin. 2007. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20:23-38.51.
51. Yamamoto, T., et al. 2007. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur. J. Pharmacol. 557: 1-8.
52. Yao, S. Y., et al. 1997. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J. Biol. Chem. 272:28423-28430.
53. Zhang, J., et al. 2007. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 26:85-110.